Currently, there are 682.48M common shares owned by the public and among those 309.35M shares have been available to trade.
The company’s stock has a 5-day price change of 1.27% and -3.61% over the past three months. OPK shares are trading 5.96% year to date (YTD), with the 12-month market performance down to -1.23% lower. It has a 12-month low price of $0.85 and touched a high of $1.76 over the same period. OPK has an average intraday trading volume of 3.99 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.17%, 4.45%, and 15.36% respectively.
Institutional ownership of Opko Health Inc (NASDAQ: OPK) shares accounts for 30.36% of the company’s 682.48M shares outstanding.
It has a market capitalization of $1.08B and a beta (3y monthly) value of 1.63. The earnings-per-share (ttm) stands at -$0.19. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.49% over the week and 4.69% over the month.
Analysts forecast that Opko Health Inc (OPK) will achieve an EPS of 0 for the current quarter, 0 for the next quarter and 0 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0 while analysts give the company a high EPS estimate of 0. Earnings per share for the fiscal year are expected to increase by 12.00%, and -31.06% over the next financial year. EPS should grow at an annualized rate of 12.00% over the next five years, compared to 1.56% over the past 5-year period.
Looking at the support for the OPK, a number of firms have released research notes about the stock. Barrington Research stated their Outperform rating for the stock in a research note on June 29, 2023, with the firm’s price target at $2. H.C. Wainwright coverage for the Opko Health Inc (OPK) stock in a research note released on December 15, 2022 offered a Buy rating with a price target of $3. Barrington Research was of a view on January 24, 2022 that the stock is Mkt Perform, while Ladenburg Thalmann gave the stock Buy rating on June 21, 2021, issuing a price target of $7. Piper Jaffray on their part issued Overweight rating on November 25, 2019.
